Instruction for use: Berlinsulin H 30/70 U-40

ATX Code A10AB01 Human insulin

Active substance Insulin biphasic [human semisynthetic]

Pharmacological group

Insulins

Nosological classification (ICD-10)Z31.1 Artificial insemination

E10 Insulin-dependent diabetes mellitus

Decompensation of carbohydrate metabolism, Diabetes mellitus, Diabetes insulin sugar, Diabetes mellitus type 1, Diabetic ketoacidosis, Insulin-dependent diabetes, Insulin-dependent diabetes mellitus, Coma hyperosmolar non-ketoacidotic, Labile form of diabetes mellitus, Violation of carbohydrate metabolism, Type 1 diabetes mellitus, Type I diabetes mellitus, Insulin-dependent diabetes mellitus, Type 1 diabetes mellitus

E11 Non-insulin-dependent diabetes mellitus

Acetonuric diabetes, Decompensation of carbohydrate metabolism, Diabetes insulin-independent sugar, Diabetes sugar type 2, Type 2 Diabetes, Non-insulin-dependent diabetes, Non-insulin dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Insulin resistance, Insulin resistant diabetes mellitus, Coma lactobacillus diabetic, Violation of carbohydrate metabolism, Type 2 diabetes mellitus, Diabetes mellitus type II, Diabetes mellitus in adulthood, Diabetes mellitus in old age, Diabetes insulin-independent, Diabetes mellitus type 2, Sugar insulin-independent diabetes type II

Composition and form of release

1 ml of the suspension for injection contains human insulin 40 ED (30% soluble normal insulin and 70% crystalline suspension with protamine) and protamine sulfate 0.10 mg (corresponding to 0.076 mg protamine base); In bottles of 10 ml, in a box of 1 pc.

pharmachologic effect

Pharmacological action - hypoglycemic.

It interacts with the specific receptor of the plasma membrane and penetrates into the cell, where it stimulates the phosphorylation of cellular proteins, activates glycogen synthase, pyruvate dehydrogenase, hexokinase, inhibits fat lipase and lipoprotein lipase. In combination with the receptor of the plasma membrane facilitates the penetration of glucose into cells, enhances the absorption of glucose by tissues and promotes its conversion into glycogen. Increases the glycogen reserve in muscles, stimulates the synthesis of peptides.

Clinical Pharmacology

It refers to drugs with an average duration of action: the effect reaches a maximum within 1-8 hours and lasts 14-16 hours.

Indications

All forms of diabetes mellitus (I and II type).

Dosing and Administration

Usually the daily dose is divided into two injections in a ratio of 2: 1 (two-thirds in the morning and one-third in the evening), injected sc (not IV) for 30-45 minutes before breakfast and dinner. In special cases - in / m. With each injection, the injection site is changed.

storage conditions

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiry date printed on the package.